Tilray Inc. is dedicated to the research, cultivation, production and distribution of medicinal cannabis and cannabinoids. The company is headquartered in Leamington, Canada.
| Revenue (TTM) | $963.10M |
| Gross Profit (TTM) | $282.63M |
| EBITDA | $12.69M |
| Operating Margin | -6.23% |
| Return on Equity | -9.38% |
| Return on Assets | -1.64% |
| Revenue/Share (TTM) | $8.12 |
| Book Value | $11.29 |
| Price-to-Book | 0.37 |
| Price-to-Sales (TTM) | 0.47 |
| EV/Revenue | 0.833 |
| EV/EBITDA | 80.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 22.70% |
| Shares Outstanding | $147.79M |
| Float | $144.36M |
| % Insiders | 1.59% |
| % Institutions | 10.13% |
Volatility is currently expanding
Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West
CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal's National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical's EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.
Tilray reported Q1-2027 financial results last week with increasing revenue from its BrewDog operations; Cannabis revenue decreased. The company expects its new beer assets along with its international cannabis operations to continue to drive growth. The company reported a net loss and negative free cash flow.
Tilray reported disappointing fiscal Q1 results, missing revenue estimates despite management highlighting record sales. TLRY's revenue growth was driven solely by the BrewDog acquisition; core cannabis sales declined 13%, and the adjusted bottom line swung to a loss. Cash burn surged to $23.4 million, and share dilution remains severe, with shares outstanding up over 31% year-over-year.
Tilray Brands TodayTLRYTilray Brands$3.44 -0.15 (-4.04%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$3.38▼$20.20Price Target$6.38Add to WatchlistWhen investors hear talk of U.S. cannabis reform, they often look at major Canadian operators.
Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript
Tilray Brands NASDAQ: TLRY reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
Tilray Inc (NASDAQ:TLRY), the cannabis and consumer products company, reported record first-quarter revenue of $257.1 million, up 23% from a year earlier, driven by strong growth in beverages and international markets. Gross profit rose 35% to $77.5 million, while gross margin expanded to 30% from 27%, as the company continued to improve profitability across its businesses.
Tilray Brands Inc. (NASDAQ:TLRY) reported a first-quarter 2027 adjusted loss of 2 cents per share on Thursday, beating the consensus loss of 20 cents.
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TLRY and any ticker you trade — then tracks every position and per-strategy win rate.
